Research Progress on the Relationship Between Radiation Enteritis and Gut Microbiota Dysbiosis Authors: Jingru Xu, Yulin Liu, Yilin Xiao, Yuxing Chen, Enqing Meng, Min Jin, Mengjiao Wu, Yan Zong, Hongli Liu Published: 2026 ABSTRACT AbstractRadiation enteritis (RE) is the most common complication of pelvic radiotherapy, often manifesting as diarrhea, hematochezia, and tenesmus. In some cases, it progresses to chronic radiation enteritis, leading to intestinal fibrosis and fistula formation, which severely impacts patients’quality of life and prognosis. Current therapeutic strategies for RE include radioprotective agents, surgery, nutritional support, and symptomatic management. However, their efficacy remains limited. The gut microbiota, a complex microbial community residing in the human digestive tract, is closely linked to human health. Numerous studies have identified gut microbiota dysbiosis in the context of RE. This review illustrates the intricate relationship between RE and the gut microbiota, focusing on the underlying mechanisms of their interaction. It also introduces emerging therapeutic strategies targeting the gut microbiota for RE, including engineered probiotics, washed microbiota transplantation (WMT), and ROS-scavenging nanomaterials, offering novel insights for its diagnosis and treatment. Introduction Radiotherapy is a cornerstone in the treatment of malignant tumors. Patients undergoing radiotherapy for pelvic, abdominal, or retroperitoneal malignancies frequently experience adverse effects such as diarrhea, hematochezia, tenesmus, abdominal pain, and obstruction, which are collectively termed RE. This condition profoundly impairs patients’ quality of life and can disrupt subsequent treatment courses. RE can affect the small intestine, colon, and rectum. Clinical manifestations are diverse. Acute symptoms typically manifest within 1–2 weeks of commencing radiotherapy, primarily including diarrhea, abdominal pain, obstruction, tenesmus, mucous stools, and even hematochezia.1 Chronic symptoms can persist for months or years, and advanced stages may be complicated by severe conditions such as intestinal obstruction, perforation, fistulas, refractory bleeding, and malnutrition, potentially leading to mortality.2 Unlike acute RE, chronic fibrotic disease is often refractory to medical management and may require surgical intervention.2 Current management of RE primarily relies on symptomatic and supportive care. Antidiarrheal agents, like loperamide and smectite, may alleviate acute diarrhea, while antispasmodics, such as anisodamine, can be used for abdominal pain relief. Surgical intervention is reserved for severe chronic complications, such as fistulas, obstructions, or perforations. Despite these options, the overall effectiveness of current treatments remains limited. Radiation Enteritis and the Gut Microbiota: A Vicious Cycle The relationship between RE and the gut microbiota is complex and bidirectional. Multiple studies have demonstrated that radiation exposure induces bacterial translocation and gut microbiota dysbiosis.3,4 Conversely, this dysbiosis can exacerbate inflammatory damage through various mechanisms. In essence, radiation-induced dysbiosis and dysbiosis-exacerbated inflammation are mutually reinforcing. Radiation as the Initiator: Direct Host Injury and Dysbiosis Pathophysiology of RE involves multiple interconnected factors: Reactive oxygen species (ROS) generated by radiation-induced water hydrolysis directly damage DNA integrity, leading to cell death and activation of inflammatory pathways, which promotes the release of pro-inflammatory cytokines such as IL - 1β, IL - 6, TGF - β, and TNF – α.5 Meanwhile, the intestinal mucosal barrier is damaged by the disruption of tight junction proteins. (eg, occludin, claudin, ZO - 1, ZO - 2) This increases permeability and leads to “leaky gut”.6 Intestinal stem cells (ISCs) undergo mitotic arrest or cell death following radiation exposure. Disruption of key signaling pathways like Wnt, Notch, and PI3K/AKT results in the destruction of crypt architecture.7 Chronic injury manifests as persistent microvascular endothelial damage, leading to obliterative endarteritis and local ischemia. This, in turn, activates the TGF - β1/Smad3 pathway, stimulating CTGF - mediated collagen deposition and tissue fibrosis.8 The pathophysiological mechanisms of radiation-induced intestinal injury are illustrated in Figure 1. Figure 1Pathophysiological Mechanisms of Radiation-Induced Intestinal Injury. Radiation exposure triggers multiple interconnected pathological mechanisms: Direct DNA damage via ROS generation leads to cell death and inflammatory pathway activation. Intestinal stem cells (ISCs) undergo mitotic arrest, disrupting crypt architecture. Disruption of tight junction proteins increases intestinal permeability. Chronic phase involves microvascular damage and TGF-β-mediated fibrosis. Black arrows (→) indicate causal relationships; upward arrows (↑) denote increased expression or activity (eg, cytokines, ROS, collagen); downward arrows (↓) denote decreased expression (eg, tight junction proteins, ISC proliferation). Created with BioRender.com.The diagram illustrates the pathophysiological mechanisms of radiation-induced intestinal injury. Radiation exposure leads to microbial dysbiosis, characterized by a decrease in beneficial bacteria and an increase in harmful bacteria. This results in tight junction damage in the intestinal lining. DNA damage occurs via reactive oxygen species, leading to dying intestinal stem cells and activation of inflammation pathways. Cytokines such as interleukin 1 beta, interleukin 6, transforming growth factor beta and tumor necrosis factor alpha are involved. Tight junctions are detailed with components like junctional adhesion molecule, occludin and claudin. The chronic phase involves microvascular endothelial dysfunction and collagen deposition, leading to fibrosis.Radiation causes intestinal issues: microbial imbalance, DNA damage, inflammation, junction harm and fibrosis. Pathophysiological Mechanisms of Radiation-Induced Intestinal Injury. Radiation exposure triggers multiple interconnected pathological mechanisms: Direct DNA damage via ROS generation leads to cell death and inflammatory pathway activation. Intestinal stem cells (ISCs) undergo mitotic arrest, disrupting crypt architecture. Disruption of tight junction proteins increases intestinal permeability. Chronic phase involves microvascular damage and TGF-β-mediated fibrosis. Black arrows (→) indicate causal relationships; upward arrows (↑) denote increased expression or activity (eg, cytokines, ROS, collagen); downward arrows (↓) denote decreased expression (eg, tight junction proteins, ISC proliferation). Created with BioRender.com. Concurrently, radiation has been reported to induce gut microbiota dysbiosis in both clinical cohorts and animal models, although the specific compositional shifts vary across studies. Several investigations have observed a trend toward increased relative abundance of Proteobacteria and decreased Firmicutes and Prevotella; however, these findings are not universal and may be influenced by tumor type, radiation dose and field, sampling timepoint, geographic factors, and sequencing methodology. At the ecological level, multiple studies report decreased α-diversity (reduced species richness and evenness) and increased β-diversity (greater inter-individual heterogeneity in community structure), suggesting an overall trend toward ecological destabilization, though the magnitude of these changes varies considerably. 16S rRNA sequencing studies have identified recurrent, though not entirely consistent, alterations in the gut microbiota of RE patients. A reduction in taxa within the phylum Firmicutes (including genera such as Faecalibacterium and Prevotella and a relative enrichment of Proteobacteria have been reported in several cohorts, but these patterns should be interpreted cautiously given the functional diversity within these broad taxonomic groups. Notably, changes in Bacteroidaceae have shown conflicting results across studies—being reported as increased in one cohort3 but decreased in another9—highlighting the influence of study-specific variables. A decrease in the Firmicutes/Bacteroidetes ratio has been observed in multiple studies, though it remains unclear whether this represents a mechanistically meaningful signature or a general indicator of ecological disruption. Several researchers have explored gut microbiota features as potential biomarkers for RE. Wang et al conducted a study of 18 cervical cancer patients undergoing radiotherapy, identifying Megamonas, Novosphingobium, and Prevotella as potential markers for radiation proctocolitis.10 Another study employing a grading system of RE found abnormally elevated levels of Erysipelatoclostridium and its metabolite ptilosteroid A in patients with Grade 2 RE.4 However, subsequent research suggested that the predictive power of single genera may be limited. A prospective study on prostate cancer patients proposed that a multi - genus predictive model holds greater clinical value. Specifically, a baseline microbiota profile characterized by Faecalibacterium <15%, Bacteroides ≥61%, Parabacteroides <8%, Alistipes <1%, Prevotella <1%, and Phascolarctobacterium ≥1% was associated with a significantly increased risk of developing RE.11 Zhao et al recruited 50 cervical cancer patients and proposed an RE prediction model based on enterotypes, classifying gut microbiota into three types: enterotype 1 dominated by Blautia, enterotype 2 dominated by Escherichia - Shigella, and enterotype 3 dominated by Faecalibacterium. Results showed that enterotype 2 (Escherichia - Shigella) was significantly associated with the occurrence of RE, suggesting this microbial pattern may serve as an important indicator of a high risk of RE.12 High - throughput 16S rRNA sequencing comparing pre - and post - irradiation samples revealed an increase in Corynebacterium and a decrease in Alistipes abundance.11 These features are potentially linked to adverse health outcomes and offer clues to RE pathogenesis. Table 1 and Table 2 below show differences in gut microbiota between healthy controls and RE patients and potential biomarkers of RE. Detailed comparisons of gut microbiota composition between healthy controls and RE patients from multiple cohorts are presented in Table 1. Potential microbial biomarkers for RE identified in human clinical cohorts and animal models are summarized in Table 2. Notably, most biomarkers have been identified in small-scale human studies or animal models; their clinical validity requires prospective validation in larger, multicenter cohorts. Table 1Differences in Gut Microbiota Between Healthy Controls and RE PatientsTimeSourceResultsSequencing MethodSample SizeSample TypeReferences2015ChinaFirmicutes/Bacteroidetes ratio decreased. Bacteroides, Clostridium_XIVa increased. Faecalibacterium, Lachnospiracea, Oscillibacter, Roseburia, and Streptococcus decreased.16SrRNA20 pelvic RT patients, 4 controlsFeces[3]2019ChinaRE patients showed increased α-diversity and decreased β-diversity. Relative abundance of Proteobacteria (phylum), Gammaproteobacteria (class), Enterobacteriaceae, Phyllobacteriaceae, Beijerinckiaceae (family) significantly increased; Bacteroidaceae, Ruminococcaceae (family) significantly decreased. RE patients enriched in Coprococcus.16SrRNA18 patients with cervical cancer (CCa)Feces[10]2024ChinaRE patients had lower ratios of Bacteroidetes, Proteobacteria, Actinomycetes, and Firmicutes compared to patients without RE. Patients with severe acute RE (SARE) had higher ratios of these phyla compared to non-SARE patients.16SrRNA50 CCa patients, 15 controlsFeces[9]2024MilanIncreased abundance of Bacteroides and Sutterella. Decreased abundance of Faecalibacterium and Roseburia.16SrRNA215 prostate cancer RT patientsFeces[11]2025ChinaCharacteristic alterations in SARE include Faecalibacterium (enterotype 3) and Escherichia-Shigella (enterotype 2).16SrRNA50 CCa patientsFeces[12]Abbreviations: RT, radiotherapy; CCa, cervical cancer; SARE, severe acute radiation enteritis. Table 2Potential BiomarkersTimeSourceResultsSequencing MethodSample SizeSpeciesSample TypeReferences2022ChinaErysipelatoclostridium and its metabolite ptilosteroid A may serve as markers for Grade 2 RE.16SrRNA16 CCa, 1 endometrial cancer patientHuman (cervical cancer)Feces[4]2019ChinaMegamonas, Novosphingobium, and Prevotella identified as potential biomarkers for RE.16SrRNA18 CCa patientsHuman (cervical cancer)Feces[10]2023ChinaDose-specific biomarkers in rats: 0Gy: Veillonellaceae; 2Gy: Firmicutes; 4Gy: Dehalobacterium and Dehalobacteriaceae; 6Gy: Odoribacter; 8Gy: Anaerotruncus, Holdemania, Proteus, Bilophila, Desulfovibrionales, Deltaproteobacteria.16SrRNASD ratsAnimal (SD rats)Midcolon contents[13]2024MilanLow pre-radiotherapy α-diversity is an independent predictor of acute gastrointestinal toxicity.16SrRNA215 prostate cancer RT patientsHuman (prostate cancer)Feces[11]Abbreviations: CCa, cervical cancer; RT, radiotherapy; RE, radiation enteritis. Table 1Differences in Gut Microbiota Between Healthy Controls and RE PatientsTimeSourceResultsSequencing MethodSample SizeSample TypeReferences2015ChinaFirmicutes/Bacteroidetes ratio decreased. Bacteroides, Clostridium_XIVa increased. Faecalibacterium, Lachnospiracea, Oscillibacter, Roseburia, and Streptococcus decreased.16SrRNA20 pelvic RT patients, 4 controlsFeces[3]2019ChinaRE patients showed increased α-diversity and decreased β-diversity. Relative abundance of Proteobacteria (phylum), Gammaproteobacteria (class), Enterobacteriaceae, Phyllobacteriaceae, Beijerinckiaceae (family) significantly increased; Bacteroidaceae, Ruminococcaceae (family) significantly decreased. RE patients enriched in Coprococcus.16SrRNA18 patients with cervical cancer (CCa)Feces[10]2024ChinaRE patients had lower ratios of Bacteroidetes, Proteobacteria, Actinomycetes, and Firmicutes compared to patients without RE. Patients with severe acute RE (SARE) had higher ratios of these phyla compared to non-SARE patients.16SrRNA50 CCa patients, 15 controlsFeces[9]2024MilanIncreased abundance of Bacteroides and Sutterella. Decreased abundance of Faecalibacterium and Roseburia.16SrRNA215 prostate cancer RT patientsFeces[11]2025ChinaCharacteristic alterations in SARE include Faecalibacterium (enterotype 3) and Escherichia-Shigella (enterotype 2).16SrRNA50 CCa patientsFeces[12]Abbreviations: RT, radiotherapy; CCa, cervical cancer; SARE, severe acute radiation enteritis. Differences in Gut Microbiota Between Healthy Controls and RE Patients Abbreviations: RT, radiotherapy; CCa, cervical cancer; SARE, severe acute radiation enteritis. Table 2Potential BiomarkersTimeSourceResultsSequencing MethodSample SizeSpeciesSample TypeReferences2022ChinaErysipelatoclostridium and its metabolite ptilosteroid A may serve as markers for Grade 2 RE.16SrRNA16 CCa, 1 endometrial cancer patientHuman (cervical cancer)Feces[4]2019ChinaMegamonas, Novosphingobium, and Prevotella identified as potential biomarkers for RE.16SrRNA18 CCa patientsHuman (cervical cancer)Feces[10]2023ChinaDose-specific biomarkers in rats: 0Gy: Veillonellaceae; 2Gy: Firmicutes; 4Gy: Dehalobacterium and Dehalobacteriaceae; 6Gy: Odoribacter; 8Gy: Anaerotruncus, Holdemania, Proteus, Bilophila, Desulfovibrionales, Deltaproteobacteria.16SrRNASD ratsAnimal (SD rats)Midcolon contents[13]2024MilanLow pre-radiotherapy α-diversity is an independent predictor of acute gastrointestinal toxicity.16SrRNA215 prostate cancer RT patientsHuman (prostate cancer)Feces[11]Abbreviations: CCa, cervical cancer; RT, radiotherapy; RE, radiation enteritis. Potential Biomarkers Abbreviations: CCa, cervical cancer; RT, radiotherapy; RE, radiation enteritis. Despite the convergence of several studies on general trends (eg, reduced diversity, shifts in Firmicutes/Proteobacteria balance), cross-study heterogeneity remains a prominent feature of this field. For example, Bacteroidaceae was reported to be increased in one study3 but decreased in another.9 And the specific genera implicated as biomarkers differ considerably across cohorts. Such discrepancies likely arise from multiple confounding factors, including differences in tumor type, radiation field and dose, fractionation schedule, sampling timepoint relative to treatment course, sample size, geographic location, baseline diet, concurrent antibiotic use, and sequencing platform (16S rRNA vs shotgun metagenomics). Furthermore, most existing studies are cross-sectional in design with relatively small sample sizes, limiting their statistical power and generalizability. Therefore, a single genus is unlikely to serve as a reliable universal predictor of RE. Multi-genus predictive models, integration with metabolomics or metatranscriptomics, and large-scale prospective longitudinal studies with standardized protocols are needed to identify robust, clinically actionable biomarkers. Dysbiosis Exacerbates RE: Three Pathways Metabolic Disruption (SCFAs, Bile Acids, Tryptophan) The gut microbiota communicates with the host through key metabolites, including short-chain fatty acids (SCFAs), amino acid derivatives, and bile acids, eliciting various biological effects. Radiation-induced dysbiosis disrupts the production of these metabolites, thereby inducing or exacerbating intestinal injury. The regulatory roles of key gut microbial metabolites, including SCFAs, bile acids, and tryptophan derivatives, are depicted in Figure 2. Figure 2Key Microbial Metabolite Pathways in Radiation Enteritis. The gut microbiota regulates intestinal homeostasis through three metabolite pathways: (Left) SCFAs activate GPR43/GPR109a on Tregs to suppress inflammation via IL-10. (Middle) Primary bile acids (CA, CDCA) synthesized in the liver are converted to secondary BAs (LCA, DCA, UDCA) by gut bacterial enzymes (BSH, BAI); secondary BAs activate TGR5 on ISCs, triggering SRC-mediated YAP1 upregulation and epithelial proliferation. (Right) Microbial tryptophan metabolites (I3A, IPA, IAA) activate AhR in ILC3s, promoting IL-22 secretion and crypt regeneration. Black arrows (→) indicate signaling or metabolic flow; upward arrows (↑) denote upregulation or increased activity; color-coded backgrounds distinguish the three pathways. Created with BioRender.com.A color segmented infographic shows three parallel routes by which gut microbes influence the intestinal lining. Left panel: bacterial fermentation products move toward receptors on regulatory T cells, leading to IL 10 release and a downward effect on inflammation. Center panel: liver-derived bile acids enter the gut, are modified by microbial enzymes, then signal through a receptor on intestinal stem cells to activate intracellular mediators and drive epithelial cell proliferation. Right panel: dietary tryptophan is converted by microbes into indole-like compounds that signal in ILC3 immune cells, inducing IL 22 and supporting regeneration of intestinal crypt structures. Arrows depict direction of conversion and signaling and icons represent microbes, metabolites, receptors and tissue outcomes.Three-panel gut diagram linking microbial products to immune calming, epithelial growth and crypt repair. Key Microbial Metabolite Pathways in Radiation Enteritis. The gut microbiota regulates intestinal homeostasis through three metabolite pathways: (Left) SCFAs activate GPR43/GPR109a on Tregs to suppress inflammation via IL-10. (Middle) Primary bile acids (CA, CDCA) synthesized in the liver are converted to secondary BAs (LCA, DCA, UDCA) by gut bacterial enzymes (BSH, BAI); secondary BAs activate TGR5 on ISCs, triggering SRC-mediated YAP1 upregulation and epithelial proliferation. (Right) Microbial tryptophan metabolites (I3A, IPA, IAA) activate AhR in ILC3s, promoting IL-22 secretion and crypt regeneration. Black arrows (→) indicate signaling or metabolic flow; upward arrows (↑) denote upregulation or increased activity; color-coded backgrounds distinguish the three pathways. Created with BioRender.com. Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are beneficial end - products of bacterial fermentation. The major SCFA - producing bacteria are Firmicutes, Bacteroidetes, Actinobacteria, Verrucomicrobia, and Lachnospiraceae.14 SCFAs exert anti - inflammatory effects by inhibiting the NF -κB and STAT1 pathways, thus suppressing the production of pro - inflammatory cytokines.15 Butyrate also promotes intestinal barrier repair by regulating Treg differentiation and IL - 10 secretion via the GPR43/GPR109a signaling axis. Studies in germ - free mice confirm that SCFA deficiency exacerbates RE.16 Decreased SCFA concentrations have been observed after radiotherapy, which is attributable to the reduction of SCFA - producing bacteria and contributes to intestinal barrier damage.17 Bile acids (BAs) are classified into two categories based on their origin: primary BAs (CA, CDCA) are synthesized de novo in the liver by hepatocytes, while secondary BAs (LCA, DCA, UDCA) are generated through microbial biotransformation of primary BAs in the colon. Certain gut bacteria, including Bacteroides, Clostridium, Lactobacillus, and Bifidobacterium, express bile salt hydrolase (BSH) and bile acid-inducible enzymes (BAI), which catalyze this conversion.18 BAs can promote intestinal epithelial regeneration by activating the TGR5 receptor on intestinal stem cells (ISCs). TGR5 activation enhances YAP1 nuclear translocation and transcriptional activity, partly through SRC kinase-mediated signaling. This pathway promotes ISC proliferation and epithelial repair.19 Guo et al revealed that irradiated mice show a decreased relative abundance of secondary BAs and an increase in primary BAs, with LCA showing the most pronounced change.20 LCA promotes epithelial regeneration by activating FXR/TGR5 receptors and enhancing YAP1 expression in ISCs. Furthermore, treatment with a bile acid mixture (BAmix) or LCA enhanced post - irradiation crypt formation and reduced inflammation in mice, potentially mitigating RE.19 Post - radiation decline in these genera can lead to intestinal bile salt accumulation, potentially inducing bile acid malabsorption diarrhea.21 Tryptophan (Trp) metabolism in the gut is significantly influenced by the microbiota. Microbiomes like Escherichia coli and Clostridium convert Trp into indole derivatives such as indole - 3 - aldehyde (IAld), indole - 3 - acetic acid (IAA), indole - 3 - propionic acid (IPA), indole - 3 - acetaldehyde (IAAld), and indoleacrylic acid.22 These indole derivatives act as AhR ligands to modulate host physiology by activating AhR. For example, they can stimulate IL - 22 secretion from type 3 innate lymphoid cells (ILC3s) via AhR activation, synergizing with Wnt signaling to promote crypt regeneration.23 Researchers have found that reduced levels of tryptophan metabolites like IAA, indole - 3 - ethanol (IEt), and IAAld in irradiated mice contribute to intestinal damage.24 Fecal I3A levels decrease in irradiated mice, and I3A administration protects against radiation injury by activating the AhR/IL - 10/Wnt pathway and enhancing the abundance of probiotic bacteria.25 Similarly, fecal IPA levels decline post - irradiation, and IPA supplementation mitigates radiation toxicity, potentially by preserving acyl - CoA - binding protein.26 These studies collectively suggest that supplementation with specific tryptophan metabolites or fecal microbiota transplantation (FMT) could ameliorate RE. Pro-Inflammatory Immune Activation A healthy microbiome contributes to maintaining a state of low - grade physiological inflammation in the gut, which helps suppress more severe inflammatory responses. Commensal and probiotic bacteria can inhibit the NF - κB pathway and TLR signaling, thereby reducing the expression of pro - inflammatory cytokines and alleviating tissue inflammation. For instance, Bifidobacterium can suppress LPS - induced NF - κB activation.27 Faecalibacterium prausnitzii secretes a 15kDa anti - inflammatory protein that inhibits NF - κB activation and IL - 8 expression.28 Clostridium subcluster XIVa can modulate intestinal polyamine secretion, thus regulating TLR - 2 signaling and alleviating inflammation.29 Activation of the NF - κB pathway and increased expression of inflammatory mediators like IL - 1β, IL - 6, and IL - 8 have been observed in many studies of RE, which is linked to radiation - induced dysbiosis.30 Epithelial Barrier Breakdown The intestinal epithelial barrier is a multi - layered structure. The outer layer comprises the mucus layer, antimicrobial peptides (AMPs), secretory IgA (sIgA), and the gut microbiota. The middle layer consists of intestinal epithelial cells, and the inner layer contains immune cells. Bacterial components such as LPS and peptidoglycan can stimulate mucus secretion by epithelial cells.31 The epithelial cells in the middle layer are interconnected by junctional complexes, including tight junctions (TJs), gap junctions, adherens junctions, and desmosomes, which are crucial for barrier integrity. In RE models, reduced expression of tight junction proteins (ZO - 1, occludin, ZO - 2) has been observed, indicating barrier disruption associated with radiation - induced dysbiosis.6 Probiotics have restorative effects on TJs. Strains such as Bifidobacterium infantis Y1, Escherichia coli Nissle 1917, and Lactobacillus plantarum have been shown to increase the expression of TJ proteins like ZO - 1, ZO - 2, and occluding.32 Dysbiosis Promotes Chronic RE: Intestinal Fibrosis Chronic radiation enteritis, which can manifest months to years after radiotherapy, is characterized by progressive intestinal fibrosis, stricture formation, fistulae, and refractory bleeding. Unlike acute RE, which is typically self-limiting or responsive to conservative management, chronic fibrotic disease is often irreversible and may necessitate surgical resection.2 The pathogenesis of chronic RE is multifactorial, involving persistent microvascular injury, hypoxia, chronic inflammation, and aberrant tissue remodeling.33 Intestinal fibrosis results from excessive deposition and dysregulated remodeling of extracellular matrix (ECM) components, particularly collagen types I and III, driven primarily by the TGF-β/Smad signaling axis.34 Microbiota’s Role in Fibrogenesis: The contribution of gut dysbiosis to chronic fibrosis is increasingly recognized, though mechanistic understanding remains incomplete.35 Zhao et al observed persistent gut dysbiosis alongside upregulation of α-SMA (a myofibroblast marker) and TGF-β in a chronic RE mouse model; supplementation with nicotinamide mononucleotide (NMN) modulated the microbiota composition and attenuated fibrosis.36 Animal models of chronic bacterial infection provide additional evidence: chronic Salmonella colonization in mice increases expression of TGF-β1, CTGF, and IGF-I, inducing severe intestinal fibrosis reminiscent of human Crohn’s disease strictures.37 These findings suggest that sustained microbial dysbiosis, even in the absence of overt infection, may perpetuate pro-fibrotic signaling.38 Microbial Metabolites as Modulators: Metabolites derived from commensal bacteria can exert anti-fibrotic effects. SCFAs, particularly butyrate, have been shown to inhibit intestinal fibrosis by suppressing TGF-β and α-SMA expression and promoting regulatory T cell differentiation.32 Extracellular vesicles derived from Faecalibacterium prausnitzii alleviate chronic intestinal fibrosis through macrophage metabolic reprogramming, highlighting the therapeutic potential of specific commensal-derived products.39 Conversely, pro-inflammatory microbial components—such as lipopolysaccharide (LPS)—can activate intestinal fibroblasts via TLR-4, stimulating NF-κB signaling, collagen contraction, and matrix deposition, thereby contributing to a pro-fibrotic microenvironment.40 Distinct Microbial Signatures in Chronic vs Acute RE: While acute RE is associated with a depletion of SCFA-producing taxa and expansion of Proteobacteria3 the microbiota profile of chronic fibrotic RE remains poorly characterized. Preliminary evidence from other chronic inflammatory conditions suggests that chronic dysbiosis may involve a more stable, low-diversity state dominated by mucin-degrading and pro-inflammatory bacteria.41 However, longitudinal studies tracking microbial transitions from acute injury to chronic fibrosis are scarce, limiting our ability to identify stage-specific biomarkers or therapeutic windows. Therapeutic Implications: Unlike acute RE, for which probiotics and FMT have shown promise42 anti-fibrotic microbiota-targeted interventions remain largely unexplored. Whether early microbiota restoration can prevent fibrosis progression, or whether established fibrosis can be reversed by microbial modulation, are critical unanswered questions. Candidate strategies include sustained SCFA supplementation, bile acid receptor agonists (eg, FXR or TGR5 modulators), and engineered bacteria designed to deliver anti-fibrotic payloads (eg, TGF-β inhibitors or matrix metalloproteinases) locally to the fibrotic intestine.43 Transmissibility of Dysbiosis-Induced Susceptibility Research suggests that radiation-induced dysbiosis can increase susceptibility to RE. Mclaughlin et al demonstrated that germ-free mice are more resistant to radiation injury than conventional mice,44 underscoring the critical role of the gut microbiota in RE pathogenesis. Microbiota dysbiosis, characterized by an increase in pro-inflammatory bacteria like E. coli and a decrease in protective bacteria, can heighten the intestine’s susceptibility to inflammation.45 Recent studies have shown that transplanting fecal microbiota from irradiated mice into healthy recipient mice renders them more susceptible to radiation damage, evidenced by increased IL-1β expression and more severe intestinal inflammation upon subsequent challenge.46 Therapeutic Strategies for RE: From Microbiota Modulation to Host Protection Given the limited efficacy of current symptomatic treatments, novel strategies have been explored. These can be categorized by evidence level: (1) probiotics and FMT have clinical case data but lack large RCTs; (2) microbial metabolites (SCFAs, indoles) show promise in animal models only; (3) nanomaterials remain in preclinical stages and primarily act through ROS scavenging and ferroptosis inhibition rather than direct microbiota modulation, with microbiota changes being secondary to reduced inflammation. Probiotics and Prebiotics Compared to conventional pharmaceuticals, probiotics generally exhibit lower toxicity and fewer adverse effects, which has led to their widespread use in managing gastrointestinal disorders. Probiotics exert antioxidant effects by producing enzymes such as catalase, superoxide dismutase (SOD), and glutathione (GSH), which can scavenge radiation - induced reactive oxygen species (ROS).47 Probiotic supplementation can help restore gut microbial homeostasis, increasing the abundance of beneficial taxa like Akkermansia, Bacteroides, Blautia, Bifidobacterium, and Firmicutes.48 Lactobacillus acidophilus has been proven to repair intestinal mucosal damage in rats.49 Supplementation with Bifidobacterium and Lactobacillus acidophilus improved radiation - induced diarrhea in patients with pelvic tumors.50 Supplementation with Lactobacillus rhamnosus GG has been shown to reduce inflammatory cytokine expression, increase gut microbiota α - diversity, and enhance anti - inflammatory metabolic pathways.51 More recent research explores genetically modified recombinant probiotics. For example, Lactobacillus sakei can inhibit IL - 6 and TNF - α secretion and upregulate IL - 10 and tight junction proteins.52 Researchers have engineered it to express exogenous antioxidant genes (eg, pprI) to confer dual anti - inflammatory and antioxidant functions. Alternatively, selenium - loaded probiotics leverage the anti - inflammatory and antioxidant properties of selenium nanoparticles to treat RE.53 Wang et al engineered a probiotic Escherichia coli Nissle 1917 serving as a SOD/CAT vehicle to scavenge ROS for the prevention and treatment of RE.54 Another innovative approach involves engineering E. coli Nissle 1917 to deliver PD - 1 agonists, achieving local immune modulation to treat RE.55 Prebiotics are non - digestible carbohydrates that selectively stimulate the growth and/or activity of beneficial gut microorganisms, conferring health benefits. Prebiotics modulate the gut microbiota by serving as substrates for beneficial bacteria, promoting their growth and subsequent short - chain fatty acid (SCFA) production.56 Prebiotic supplementation has shown therapeutic potential in RE models. Researchers developed curcumin - thioketal - inulin conjugate micelles and validated their anti - inflammatory and microbiota - modulating effects in a mouse model.57 Garcia et al reported improved diarrhea outcomes in the prebiotic group using a mixture of FOS and inulin.58 Furthermore, synbiotics, which combine probiotics and prebiotics, are gaining attention. For instance, inulin hydrogel loaded with a multi - strain probiotic consortium not only protects the probiotics during gastrointestinal transit but also serves as a nutrient source. This synbiotic demonstrated superior efficacy compared to probiotics alone in treating RE, repairing the intestinal barrier, reducing inflammatory cytokines, and enhancing intestinal SCFA synthesis.59 Evidence and Limitations: Small RCTs show modest, strain-specific benefits. Key limitations: low GI survival, heterogeneous protocols, some trials report null results. Engineered probiotics (SOD/CAT-expressing) remain preclinical. Microbiota-Derived Metabolites as Therapeutic Agents Unlike live microbiota-derived metabolites or FMT, which aim to restore the microbial ecosystem as a whole, microbiota-derived metabolites represent a more defined, molecule-based approach. These include short-chain fatty acids (SCFAs), tryptophan-derived indoles, and secondary bile acids, which mediate host-microbe crosstalk and exert direct protective effects on intestinal epithelium. Evidence Level: Current evidence for therapeutic use of microbial metabolites in RE is derived exclusively from preclinical animal models. No human trials have been conducted to date. Certain microbiota-derived metabolites possess intrinsic anti-inflammatory and tissue-protective properties. SCFAs, particularly butyrate, have been shown to alleviate RE in mouse models. Indole-3-aldehyde (I3A), a tryptophan metabolite produced by the gut microbiota, is considered one of the most potent radioprotective indole derivatives.23 Oral administration of I3A promotes intestinal epithelial renewal and regeneration by activating the AhR/IL-10/Wnt3 pathway. Meanwhile, it also increases the relative abundance of radioprotective bacteria like Bifidobacterium and Lactobacillus and reduces pathogenic bacteria.25 Limitations and Future Directions: While preclinical data are promising, several barriers impede clinical translation. First, the pharmacokinetics and bioavailability of oral metabolites (eg, butyrate, I3A) in humans remain poorly characterized, and systemic absorption may be required for some effects. Second, the optimal dose, formulation, and timing of administration relative to radiation exposure are unknown. Third, most studies used total-body or high-dose abdominal irradiation in rodents, which may not accurately reflect the clinical scenario of fractionated pelvic radiotherapy in humans. Finally, it remains unclear whether exogenous metabolite supplementation can fully substitute for the complex metabolic output of a healthy microbiota. Phase I dose-escalation and safety studies in cancer patients undergoing radiotherapy are needed as a first step toward clinical validation. Fecal Microbiota Transplantation Fecal microbiota transplantation (FMT) involves transferring fecal microbiota from a healthy donor into a patient’s intestinal tract to restore a healthy microbial community. Clinically, FMT is emerging as a promising treatment for RE, particularly in patients refractory to conventional therapies. A 2022 case report described the successful treatment of recurrent RE in a 59 - year - old woman with cervical cancer using FMT from her son.42 Another 2024 case report documented significant improvement in diarrhea and hematochezia in a 64 - year - old woman with chronic RE two months after receiving FMT from a healthy 27 - year - old donor. Post - FMT, the patient’s gut microbiota showed markedly increased diversity, with a gradual increase in Firmicutes and a decrease in Proteobacteria, resembling the donor’s profile.60 Furthermore, a 2023 cohort study suggested that perioperative FMT combined with nutritional support could benefit patients with RE complicated by intestinal obstruction.61 Washed microbiota transplantation (WMT) can reduce reduced FMT-related adverse events for three times by removing pro-inflammatory effects in the fecal microbiota supernatant such as leukotriene B4, corticosterone, and prostaglandin G2. Thus, Wang et al combined Holdemanella biformis to WMT, which significantly mitigated radiation-induced injury compared with normal WMT, providing a new research paradigm in the concept of microbiome-based therapeutics.62 These cases highlight the potential of FMT in both medical and surgical management of RE. Recently, emerging technologies have been developed to improve the safety and efficacy of FMT. For instance, single-cell nanocapsule-based FMT strategies, which encapsulate individual bacterial cells within a biocompatible shell, have shown promise in protecting donor bacteria from gastric acid and enabling targeted delivery to the colon.63 Such approaches may reduce adverse events and enhance engraftment compared to conventional FMT, though they remain in early preclinical stages. Evidence and Limitations: Case reports only (n<20 total). Lack controlled trials, standardized protocols, and long-term safety data. WMT with specific strains (H. biformis) is innovative but unvalidated. Host-Protective Nanomaterials Nanomaterials primarily target host injury pathways (ROS scavenging, ferroptosis inhibition, immune modulation) rather than directly modulating microbiota. Observed microbiota changes are likely secondary to reduced inflammation. Evidence Level: Preclinical only (in vitro + animal models). No human trials. Major barriers: unknown long-term safety, manufacturing complexity, suboptimal oral bioavailability. Nanomaterials are increasingly explored for disease diagnosis and therapy because of their unique properties. Compared with traditional medicines, nanomedicines may offer enhanced chemical stability, fewer side effects, more convenient administration routes, and prolonged half - lives. Targeted delivery systems utilizing hydrogels, microspheres, or nanoparticles can enable drugs to accumulate at the site of injury and specifically target inflammatory processes. For example, hydrogels incorporating ROS scavengers are being developed for treating inflammatory diseases.64 Certain carbon - based nanomaterials, such as fullerenes65 and carbon nanotubes,66 inherently possess ROS - scavenging capabilities. This has spurred interest in their application for RE. Researchers have designed nanomaterials aimed at both ROS scavenging and gut microbiota modulation to protect against RE. Examples include carbon nanoparticle suspension injection (CNSI), which protects small intestinal crypts,67 graphdiyne nanoparticles,68 and novel sulfur - doped red fluorescent carbonized polymer dots (S - rCPDs) with excellent biocompatibility.69 Orally administered halloysite nanotube - stabilized Pickering emulsions have been shown to inhibit ferroptosis and alleviate RE. Selenium nanoparticles can modulate the cGAS - STING pathway, suppress oxidative stress, and maintain intestinal immune homeostasis.70 PD - L1 affibody (ZPD - L1) - conjugated Janus Ag/Ag2S nanoarchitectures (AMZ) have been designed not only to alleviate RE but also to enhance tumor radiosensitivity.71 The key features, evidence levels, limitations, and future directions of these microbiota-targeted strategies are summarized in Table 3. Table 3Gut Microbiota-Targeted TherapiesMechanism TypeStrategyExamplesMechanism of ActionEvidence LevelMajor LimitationsFuture DirectionsDirect microbiota modulationProbioticsL. rhamnosus GG, E. coli Nissle 1917 (engineered)ROS scavenging, tight junction upregulation, anti-inflammatory cytokinesPreclinical + small RCTs (low evidence)Strain-specific effects, low survival in GI tract, variable dosingEngineered probiotics (eg, SOD/CAT expressing), synbioticsDirect microbiota modulationPrebiotics/SynbioticsInulin, FOS; inulin hydrogel multi-strain probioticsSubstrate for beneficial bacteria, enhance SCFA productionPreclinical + one small RCTLimited clinical data, formulation complexityTargeted delivery (eg, hydrogels), combination with microbiota-derived metabolitesMicrobiota-derived signalingMicrobiota-derived metabolitesButyrate, I3A, IPAAhR activation, HDAC inhibition, epithelial regenerationPreclinical (robust)Short half-life, need for encapsulationNano-delivery, Microbiota-derived metabolites cocktailsDirect microbiota modulationFMT/WMTHealthy donor feces; washed microbiota transplantationEcosystem restoration, rebalancing of metabolitesCase series, small cohortDonor variability, infection risk, lack of standardizationSingle-cell nanocapsules, augmented FMT (eg, + H. biformis)Host-protective (ROS scavenging, ferroptosis inhibition)Nanomater-ialsCarbon nanoparticles, SeNPs, graphdiyne, Halloysite nanotubesROS scavenging, ferroptosis inhibition, immune modulationPreclinical onlyBiocompatibility, long-term safety, scale-upMultifunctional nanosystems with tumor radiosensitizationAbbreviations: FMT, fecal microbiota transplantation; WMT, washed microbiota transplantation; SCFAs, short-chain fatty acids; ROS, reactive oxygen species; SeNPs, selenium nanoparticles; AIEC, adherent-invasive Escherichia coli; SOD, superoxide dismutase; CAT, catalase. Table 3Gut Microbiota-Targeted TherapiesMechanism TypeStrategyExamplesMechanism of ActionEvidence LevelMajor LimitationsFuture DirectionsDirect microbiota modulationProbioticsL. rhamnosus GG, E. coli Nissle 1917 (engineered)ROS scavenging, tight junction upregulation, anti-inflammatory cytokinesPreclinical + small RCTs (low evidence)Strain-specific effects, low survival in GI tract, variable dosingEngineered probiotics (eg, SOD/CAT expressing), synbioticsDirect microbiota modulationPrebiotics/SynbioticsInulin, FOS; inulin hydrogel multi-strain probioticsSubstrate for beneficial bacteria, enhance SCFA productionPreclinical + one small RCTLimited clinical data, formulation complexityTargeted delivery (eg, hydrogels), combination with microbiota-derived metabolitesMicrobiota-derived signalingMicrobiota-derived metabolitesButyrate, I3A, IPAAhR activation, HDAC inhibition, epithelial regenerationPreclinical (robust)Short half-life, need for encapsulationNano-delivery, Microbiota-derived metabolites cocktailsDirect microbiota modulationFMT/WMTHealthy donor feces; washed microbiota transplantationEcosystem restoration, rebalancing of metabolitesCase series, small cohortDonor variability, infection risk, lack of standardizationSingle-cell nanocapsules, augmented FMT (eg, + H. biformis)Host-protective (ROS scavenging, ferroptosis inhibition)Nanomater-ialsCarbon nanoparticles, SeNPs, graphdiyne, Halloysite nanotubesROS scavenging, ferroptosis inhibition, immune modulationPreclinical onlyBiocompatibility, long-term safety, scale-upMultifunctional nanosystems with tumor radiosensitizationAbbreviations: FMT, fecal microbiota transplantation; WMT, washed microbiota transplantation; SCFAs, short-chain fatty acids; ROS, reactive oxygen species; SeNPs, selenium nanoparticles; AIEC, adherent-invasive Escherichia coli; SOD, superoxide dismutase; CAT, catalase. Gut Microbiota-Targeted Therapies Abbreviations: FMT, fecal microbiota transplantation; WMT, washed microbiota transplantation; SCFAs, short-chain fatty acids; ROS, reactive oxygen species; SeNPs, selenium nanoparticles; AIEC, adherent-invasive Escherichia coli; SOD, superoxide dismutase; CAT, catalase. Among these strategies, conventional probiotics have the longest history of clinical use and the most mature evidence base, albeit limited to small RCTs with modest, strain-dependent efficacy. FMT has shown encouraging signals in isolated case reports, but lacks the controlled trial data necessary for evidence-based recommendations; standardization of donor screening, preparation protocols, and patient selection criteria is urgently needed. Microbiota-derived metabolites (SCFAs, indoles) and host-protective nanomaterials remain entirely in preclinical stages, with no human safety or efficacy data. Importantly, these intervention classes differ not only in evidence maturity but also in their primary mechanisms: while probiotics, prebiotics, and FMT directly modulate the microbiota, nanomaterials primarily target host oxidative stress and immune pathways, with microbiota changes as a secondary consequence. Future research priorities include adequately powered, randomized, placebo-controlled trials for probiotics and FMT, phase I dose-escalation studies for metabolites and nanomaterials, head-to-head comparisons across modalities, and integration of microbiota profiling with clinical outcomes to identify responder biomarkers and personalize therapy selection. Discussion Radiation enteritis (RE) remains one of the most refractory complications following radiotherapy for pelvic and abdominal malignancies, posing substantial challenges to both patients and clinicians. Despite its clinical significance, current therapeutic approaches remain largely palliative, focusing on symptom control rather than addressing the core pathological drivers of the disease. In recent years, a growing body of evidence has repositioned the gut microbiota from a passive bystander to an active participant in the pathogenesis of RE. This review synthesizes current knowledge on the bidirectional crosstalk between RE and the intestinal microbiome, and highlights the emerging potential of microbiota-centered interventions. Accumulated evidence supports a vicious cycle. Data from clinical cohorts and animal models converge on a consistent theme: radiation exposure profoundly disrupts the compositional and functional architecture of the gut ecosystem. This dysbiosis is typically characterized by a decline in microbial diversity, a marked depletion of beneficial commensals—such as SCFA-producing Firmicutes and Prevotella—and an expansion of potentially detrimental phyla like Proteobacteria. Importantly, this microbial imbalance is not merely a collateral consequence of tissue injury; rather, it serves as a critical amplifier of intestinal damage via metabolic disruption (depletion of SCFAs, secondary bile acids, and AhR-activating indoles), sustained NF-κB-driven inflammation, and breakdown of the epithelial barrier. Perhaps the most compelling evidence for causality comes from transplantation studies: transferring fecal microbiota from irradiated hosts into naïve recipients confers heightened susceptibility to intestinal injury, underscoring the transmissible nature of radiation-induced inflammatory vulnerability. A critical conceptual distinction must be emphasized: current evidence primarily establishes associations rather than causation. Most human studies report correlations between microbial signatures and RE outcomes but cannot determine whether dysbiosis is a driver, consequence, or bystander phenomenon. A subset of prospective studies demonstrate predictive value—baseline microbiota profiles can stratify RE risk—yet prediction does not prove causality. Causal evidence comes largely from animal experiments: germ-free mice show reduced radiation sensitivity compared to conventional mice, and transplanting microbiota from irradiated donors to naïve recipients transmits inflammatory susceptibility. These mechanistic studies suggest that dysbiosis actively drives pathology. Nonetheless, translating causal insights from controlled animal models to the heterogeneous human clinical setting remains a formidable challenge. With this framework in mind, several key bottlenecks warrant attention. Key bottlenecks remain unresolved. First, moving from correlation to causation in human cohorts requires longitudinal multi-omics studies integrating metagenomics, metabolomics, and host transcriptomics. Most existing studies are cross-sectional or small-scale prospective designs. Animal models, while informative, often use total-body irradiation that does not fully replicate fractionated pelvic radiotherapy. Second, the molecular dialogues through which specific bacterial strains or consortia modulate host pathways—such as AhR-driven epithelial renewal or TGR5-mediated stem cell activation—require further mechanistic dissection, ideally using gnotobiotic models and organoid co-cultures. Third, the role of the microbiota–metabolite–immune axis in driving chronic fibrotic sequelae is underexplored; most studies focus on acute injury, whereas chronic RE with fibrosis and fistula formation has received limited attention. Fourth, significant heterogeneity persists across biomarker studies due to variations in patient demographics, tumor types, radiation protocols, dietary habits, and sequencing methodologies. This heterogeneity undermines the clinical utility of single-genus biomarkers and highlights the need for multi-omics integration and large-scale validation. The Chronic Fibrotic Phase Remains Underexplored. Most microbiota research in RE has focused on acute injury, with relatively little attention to chronic fibrotic sequelae. This knowledge gap is clinically significant, as chronic RE with strictures, fistulae, and malabsorption represents a major source of long-term morbidity and often requires surgical intervention. Key unanswered questions include: (1) Do distinct microbial profiles predict progression from acute to chronic RE? (2) Can microbiota-targeted interventions prevent or reverse established fibrosis? (3) What are the stage-specific roles of microbial metabolites in fibrogenesis versus fibrosis resolution? Longitudinal cohort studies with serial microbiome profiling from the acute phase through chronic fibrosis are critically needed. Preclinical models should prioritize fractionated, localized irradiation protocols over total-body exposure to better recapitulate the clinical scenario of pelvic radiotherapy. Furthermore, anti-fibrotic strategies—such as engineered bacteria delivering matrix metalloproteinases or TGF-β antagonists—warrant investigation. Therapeutic translation faces substantial hurdles. Although probiotic supplementation and FMT have shown promise, their evidence level remains low (mainly preclinical or small case series). Strain-specific effects, donor variability, lack of standardization, and long-term safety concerns (eg, infection risk with FMT) limit clinical adoption. Nanomaterials, while innovative and effective in preclinical models, are largely confined to proof-of-concept studies; questions regarding biocompatibility, metabolic fate, scalable production, and regulatory approval remain unanswered. Moreover, none of the microbiota-targeted strategies have been directly compared against each other or against standard supportive care in head-to-head trials. Future directions: from correlation to causation and from bench to bedside. We propose several priorities for advancing the field. (1) Mechanistic studies: Use germ-free mice colonized with defined bacterial consortia or specific metabolites (eg, I3A, LCA) to establish causality. Patient-derived intestinal organoids co-cultured with gut bacteria can dissect host–microbe interactions at the epithelial-stem-cell level. (2) Biomarker development: Integrate metagenomics, metabolomics, and host transcriptomics to build multi-parametric risk prediction models for RE. Prospective multicenter cohorts with standardized sampling and radiotherapy protocols are urgently needed. (3) Therapeutic innovation: Engineer next-generation probiotics with ROS-scavenging enzymes or anti-inflammatory payloads (eg, PD-1 agonists, IL-10). Develop targeted nanodelivery systems that co-deliver microbiota-derived metabolites and radioprotectants to the injured intestine. Advance FMT technologies, such as single-cell nanocapsules and washed microbiota transplantation augmented with specific beneficial strains (eg, Holdemanella biformis), to improve safety and engraftment. (4) Clinical translation: Design randomized controlled trials comparing microbiota-based interventions (eg, microbiota-derived metabolites vs FMT vs nanomaterials) with placebo or standard care, with endpoints including not only symptom relief but also mucosal healing, quality of life, and long-term fibrosis prevention. Conclusion The gut microbiota has emerged as a central regulator of intestinal homeostasis and a key determinant of radiation-induced pathology. Targeting this “hidden organ” represents a transformative approach to managing RE, shifting the therapeutic paradigm from damage control to ecosystem restoration. Although the path to clinical implementation is fraught with challenges, continued advances in mechanistic understanding and interventional technologies hold the promise of integrating precision microbiota modulation into the standard of care for radiation enteropathy in the foreseeable future.